20014-04-17 Ph.D. Molecular Medicine, San Raffaele University, Milan, Italy.
2008-11-04 Degree in Cellular and Molecular Biology, University of Bari, Italy

2021-to date Research Group Leader, Experimental Gastroenterology Unit Department of Gastroenterology and Digestive Endoscopy and Division of Immunology, San Raffaele Hospital, Italy, Università Vita-Salute San Raffaele

2017 –2021 Post-doctoral Research Scientist Department of Biomedical Sciences, ImmunoCenter, Hunimed, Italy

2014 – 2021 Post-doctoral researcher Laboratory of Gastrointestinal Immunopathology, Humanitas Clinical Institute, Milan (Italy)

2010 – 2014 Ph.D. student Division of Neuroscience, Stem Cell and Neurogenesis Unit, San Raffaele Research Institute, Milan (Italy)

2012 – 2013 Visiting Ph.D. student, supervisor Dr. Tilo Kunath. Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh (UK)

Awards

2020 Research prize for young researchers
2020-2022 Fondazione AMICI Italia Onlus 2019 Recognition as talented young researcher
2018 Humanitas Clinical and Research Institute
2017 Recognition for scientific accomplishment as an early career investigator by Digestive Disease Week (DDW), Chicago 2017

Funding

• The gut virome as a trigger for IBD: from metagenomics to pathogenesis, Fondazione Cariplo, Italy, Principal Investigator (PI)
• The role of MFSD2A in the resolution of colorectal cancer-promoting inflammation: implications for innovative therapies, Italian Ministry of Health, PI
• The role of MFSD2A in the resolution of metastatic colorectal cancer-promoting inflammation: implications for innovative therapies, Fondazione AIRC, PI
• From Nature to Bedside- Algae Based Bio Compound for Prevention and Treatment of Inflammation, Pain and IBD (ALGAE4IBD), Horizon2020, WP leader.
• Evaluation of an anti-TREM-1 treatment on an ex vivo human intestinal model (TIME), sponsored by Inotrem, euros PI
• Investigating roles of RIPK1 inhibitor for the treatment of inflammatory bowel diseases (IBD), sponsored by Sanofi-Aventis, PI 
• Definition of IBD-associated Gut Virome via Next-Generation Sequencing: Novel Insights for Disease Onset and Treatments. ECCO grant, PI
• Tofacitinib-induced molecular mechanisms causing adverse effects in patients with ulcerative colitis by exploiting a multi-omic approach to predict the risk of colon malignancies, Pfizer Inspire program, PI
• IL-23-IL-17 immune axis and the intestinal epithelial barrier in IBD, sponsored by UCB, Project co-leader
• Anti-adhesion therapies for Inflammatory Bowel Disease, sponsored by Shire-Takeda, Project leader